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Abstract
Background: Alternative treatment strategies have become essential in overcoming the problem of drug-resistant
Mycobacterium tuberculosis (Mtb). In this preliminary in vitro study, the anti-tuberculosis (anti-TB) activity of exogenous
iron chelators (xenosiderophores) such as Exochelin-MS (Exo-MS) and Deferoxamine-B (DFO-B) was evaluated against
ten multi-drug-resistant (MDR) and seven pyrazinamide-resistant (PZAR) Mtb isolates.
Methods: Mycobacteria Growth Indicator Tube-Drug Susceptibility Test was used to assess the anti-TB effect of Exo-MS
or DFO-B individually and their combinations with isoniazid (INH), rifampicin (RIF) and pyrazinamide (PZA).
Results: For the MDR-Mtb isolates, Exo-MS alone inhibited two out of the five isolates tested. Whereas, DFO-B alone
inhibited nine out of the ten MDR isolates tested. For PZA-resistant Mtb isolates, both Exo-MS and DFO-B individually
inhibited five out of the seven isolates. The MIC of Exo-MS in combination with INH, RIF and PZA remained the same.
The MIC of DFO-B decreased when tested in combination with INH, RIF and PZA.
Conclusions: Exo-MS and DFO-B were shown to have activity against drug-resistant Mtb isolates. Therefore, these
xenosiderophores may be useful adjuncts to antibiotics in overcoming the problem of drug-resistant Mtb in clinical
setting.
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Background
Tuberculosis (TB) is one of the leading infectious dis-
eases in the world today. Mycobacterium tuberculosis
(Mtb), the causative agent of TB, is mainly transmitted
from person to person through aerosols. Infections
caused by TB bacteria are usually treated with the first-
line antituberculosis drugs, namely, isoniazid (INH), ri-
fampicin (RIF), ethambutol (EMB), pyrazinamide (PZA),
and streptomycin (STR).
However, Mtb bacteria have acquired resistance over
the years to many of these drugs due to inappropriate
use, mutations in Mtb, etc. These factors have resulted
in the emergence of multi-drug-resistant TB (MDR-TB)
and extensively-drug-resistant TB (XDR-TB), which have
rendered current treatment strategies ineffective.
In MDR-TB, the organisms develop resistance to INH
and RIF, the two most important primary drugs. In
XDR-TB, the bacteria are resistant to the first-line as
well as to the second-line anti-TB drugs. XDR-TB de-
velops in about 9% of MDR-TB patients and is more
challenging to treat [1]. In 2014, globally 4,80,000 cases
of MDR-TB were reported with mortality of 1,90,000.
XDR-TB patients have been identified in about 100
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countries. As per this WHO report, India, along with
other third world countries is a high-burden country for
TB. With the aim of ending TB by 2035, WHO has initi-
ated an “End TB Strategy” [2].
Iron is a vital nutrient for all living organisms necessary
for life-sustaining cellular processes such as cell growth,
DNA synthesis, electron transport, oxygen transport, etc.
The mammalian host maintains low levels of iron using
its iron-binding proteins; about 10−18 M of circulating free
ferric (Fe3+) ions. Microorganisms synthesize small mole-
cules called siderophores (Greek “iron-carrier”) which
scavenge iron from the host to promote their own growth
[3]. Siderophore-Fe3+ ion complexes that are formed are
then transported intracellularly via specific outer mem-
brane receptor proteins by bacteria.
If Fe3+ ion is complexed with xenosiderophores (not
“self”) for a given microorganism, iron uptake may be
affected due to the absence of specific receptors in most
bacteria. A decrease in the availability of iron would
probably be detrimental to the growth of pathogens
including the drug-resistant ones. A phytosiderophore
extracted from plant root washings has been reported to
inhibit the in vitro growth of H37 Ra strain of Mtb [4].
M. smegmatis produces three siderophores: mycobactin
S (S for smegmatis), carboxymycobactin S and Exochelin
MS (Exo-MS; MS for M. smegmatis).Mtb expresses myco-
bactin T (T for tuberculosis) and carboxymycobactin T.
However, it does not produce exochelin. Therefore, Exo-
MS is a xenosiderophore for Mtb. Similarly, the commer-
cially available Deferoxamine mesylate (DFO-B), originally
extracted from Streptomyces pilosus, is also a xenosidero-
phore forMtb. Desferri forms of Exo-MS and DFO-B were
tested for their anti-TB potential alone and in combination
with drugs against MDR and PZAR-Mtb isolates by the
Mycobacteria Growth Indicator Tube – Drug Susceptibil-
ity Test (MGITTM-DST) [5].
MGIT-DST is a qualitative test used for antimycobac-
terial susceptibility testing of Mtb developed by Becton
Dickinson. A fluorescent oxygen-quenched sensor (Tris
4, 7-diphenyl-1, 10 phenanthroline ruthenium chloride
pentahydrate) embedded in silicone is present at the
base of a tube. The principle underlying the test is that
the initial concentration of dissolved oxygen in the Mid-
dlebrook 7H9 broth quenches the emission of fluores-
cence from this sensor and therefore is not visualized
under UV light. However, when actively growing Mtb
bacilli consume the available oxygen, the sensor fluo-
resces and is visualized under UV light. The intensity of
this fluorescence is directly proportional to the amount
of oxygen consumed by the Mtb bacilli for growth. The
amount of oxygen utilized by Mtb for growth in the
medium is monitored by the BACTEC MGIT system
which automatically interprets results as ‘S’(susceptible)
or ‘R’ (resistant) based on the extent of fluorescence [5].
Methods
Extraction and purification of Exo-MS from M. smegmatis
mc2155
M. smegmatis was grown in an iron-deficient medium
[6, 7] for 10 days at 37 °C with aeration [8]. Briefly,
Exo-MS was recovered from the culture supernatant
using the benzyl alcohol extraction procedure [9]. Purifi-
cation was carried out on an alumina column [10],
which removed most of the hydrophobic impurities;
Exo-MS was then eluted using a mixture of methanol
and formic acid. HR-LCMS was carried out to deter-
mine the purity of Exo-MS.
Determination of in vitro effect of Exo-MS and DFO-B on
MDR and PZA-resistant Mtb isolates by MGIT-DST method
i. Clinical isolates: To identify the drug-resistant status
of the clinical Mtb isolates, MGIT-DST was carried
out using multiple drugs that include streptomycin,
INH, RIF and ethambutol (SIRE) along with PZA and
other antibiotics. The isolates resistant to INH and
RIF – termed as MDR isolates – were used in this
study. Besides these, isolates showing resistance to
PZA were also used. The revival of the Mtb isolates
was done in Middlebrook 7H9 broth supplemented
with MGIT PANTA (reconstituted with MGIT
growth supplement).
Five MDR-Mtb isolates were used for testing
the anti-TB activity of Exo-MS alone and its
combination with INH and RIF. Ten MDR-Mtb
isolates were used for testing the activity of
DFO-B alone and its combination with INH and
RIF. Five of the MDR-Mtb isolates were also
resistant to PZA. These five and two non-MDR
isolates resistant to PZA (making a total of seven
PZA-resistant Mtb isolates) were used to evaluate
the activity of Exo-MS and DFO-B individually
and in combination with PZA.
ii. Method: MGIT-DST was used to determine the anti-
TB activity of the siderophores and their combin-
ation with drugs. The test was conducted as per the
standard protocol recommended in the BACTEC
MGIT system manual [5].
iii. Testing of siderophores and their combinations: Exo-
MS isolated in our laboratory was used for this study
at a concentration of 19 mg/mL [8]. The concentra-
tion of Exo-MS and its combinations with INH and
RIF used against MDR isolates are shown in Table 1.
Similarly, its concentration alone and in combination
with PZA against PZA-resistant isolates are shown
in Table 2.
A working stock of DFO-B (160 mg/mL) was
prepared from 250 mg/mL stock solution before use.
The concentration of DFO-B and its combinations
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with INH and RIF used against MDR isolates are
shown in Table 3. Similarly, its concentration alone
and in combination with PZA against PZA-resistant
isolates are shown in Table 4.
For each isolate, one set of tubes was supplemented
with excess ferric ammonium citrate as control to
ascertain whether the growth inhibition was solely
due to iron deprivation.
All the tubes were mixed by inverting several times
and then placed in set carriers before transferring
them into the MGIT instrument maintained at 37 °C.
The first tube in the set carrier is always the Growth
Control (GC) tube. In MGIT-DST, the GC should
have a Growth Unit (GU) value of 400 or more. If
the GU value of the drug-containing tube is <100, the
interpretation “S” is read by the MGIT instrument. If
the GU value of the drug-containing tube is ≥ 100,
the reading “R” is given by the instrument [5]. When
the GU value of the GC was 400 or greater, the tubes
were removed, scanned and a report was generated.
iv Test for bactericidal or bacteriostatic effect of the
siderophores: Determination of minimum
bactericidal concentration was carried out to test
whether the concentration of the siderophores used
had a bacteriostatic (inhibiting), or bactericidal
(killing) effect. For this test, 0.5 mL aliquots from
the tubes showing GU value <100 after 14 days
were re-inoculated into fresh Middlebrook 7H9
broth without any siderophores and antibiotics; the
tubes were incubated in the MGIT instrument for
35 days.
Results
Extraction and purification of Exo-MS from M. smegmatis
mc2155
HR-LC/MS analysis confirmed the presence of Exo-MS
[8]. Since Exo-MS was used to chelate iron, it was iso-
lated in desferri form, i.e., not saturated with iron. DFO-
B was obtained in desferri form.
Table 1 Protocol for MGIT-DST of MDR-Mtb with Exo-MS alone and in combination with INH and RIF
No Drug Initial Concentration of
the drug preparation
Volume added
to MGIT for Test
Final Concentration in
MGIT tube except GC
No. of Middle Brook tubes
GC MDR
1 INH 8.3 μg/mL 100 μL 0.1 μg/mL 1 1
2 RIF 83 μg/mL 100 μL 1.0 μg/mL 1
3 Exo-MS + INH 19 mg/mL + 8.3 μg/mL 50 μL + 100 μL 0.125 mg/mL and 0.1 μg/mL 1
4 Exo-MS + INH 19 mg/mL + 8.3 μg/mL 100 μL + 100 μL 0.25 mg/mL and 0.1 μg/mL 1
5 Exo-MS + INH 19 mg/mL + 8.3 μg/mL 200 μL + 100 μL 0.5 mg/mL and 0.1 μg/mL 1 1
6 Exo-MS + RIF 19 mg/mL + 83 μg/mL 50 μL + 100 μL 0.125 mg/mL and 1.0 μg/mL 1
7 Exo-MS + RIF 19 mg/mL + 83 μg/mL 100 μL + 100 μL 0.25 mg and 1.0 μg/mL 1
8 Exo-MS + RIF 19 mg/mL + 83 μg/mL 200 μL + 100 μL 0.5 mg and 1.0 μg/mL 1
9 Exo-MS 19 mg/mL 50 μL 0.125 mg/mL 1 1
10 Exo-MS 19 mg/mL 100 μL 0.25 mg/mL 1
11 Exo-MS 19 mg/mL 200 μL 0.5 mg/mL 1
12 Exo-MS+ FeCl3 19 mg/mL + 80 mg/mL 200 μL + 50 μL 0.5 mg/mL and 0.5 mg/mL 1
Table 2 Protocol for MGIT-DST for PZAR-Mtb with Exo-MS alone and in combination with PZA
No Drug Initial Concentration of
the drug preparation
Volume added
to MGIT for Test
Final Concentration in
MGIT tube except GC
No. of PZA tubes
GC PZAR
1 PZA 8 mg/mL 100 μL 0.1 mg/mL 1 1
2 Exo-MS + PZA 19 mg/mL + 8 mg/mL 50 μL + 100 μL 0.125 mg/mL and 0.1 mg/mL 1
3 Exo-MS + PZA 19 mg/mL + 8 mg/mL 100 μL + 100 μL 0.25 mg/mL and 0.1 mg/mL 1
4 Exo-MS + PZA 19 mg/mL + 8 mg/mL 200 μL + 100 μL 0.5 mg/mL and 0.1 mg/mL 1
5 Exo-MS 19 mg/mL 50 μL 0.125 mg/mL and 0.1 mg/mL 1 1
6 Exo-MS 19 mg/mL 100 μL 0.25 mg/mL 1
7 Exo-MS 19 mg/mL 200 μL 0.5 mg/mL 1
8 Exo-MS+ FeCl3 19 mg/mL + 80 mg/mL 200 μL + 50 μL 0.5 mg/mL and 0.5 mg/mL 1
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Inhibitory effect of Exo-MS alone and in combination with
INH and RIF on MDR-Mtb isolates in vitro
Table 5 shows the GU values of Exo-MS, Exo-MS + INH,
and Exo-MS + RIF combinations on five different isolates
of MDR-Mtb. For two of the five MDR-Mtb isolates, MIC
of Exo-MS alone was 0.5 mg/mL. No concentration below
this was inhibitory in combination with INH or RIF.
Inhibitory effect of DFO-B alone and in combination with
INH and RIF on MDR-Mtb isolates in vitro
Table 6 shows the GU values of DFO-B and DFO-B +
INH, DFO-B + RIF combinations against the ten differ-
ent isolates of MDR-Mtb isolates. For four MDR iso-
lates, MIC of DFO-B alone was 0.5 mg/mL. For five
other MDR isolates, MIC of DFO-B alone was 1.0 mg/
mL. For one of these five isolates, MIC of DFO-B +
INH and DFO-B + RIF combinations decreased to
0.5 mg/mL.
So, a total of nine out of ten MDR-Mtb isolates were
inhibited by DFO-B alone (and its combinations).
Inhibitory effect of Exo-MS and DFO-B alone and in com-
bination with PZA on PZA-resistant Mtb isolates in vitro
Table 7 shows the GU values of Exo-MS and Exo-MS +
PZA combination on seven PZA-resistant isolates.
For the two non-MDR PZA-resistant isolates, MIC of
Exo-MS alone was 0.125 mg/mL. For two MDR PZA-re-
sistant isolates, the MIC was 0.25 mg/mL. For one MDR
PZA-resistant isolate, the MIC was 0.5 mg/mL.
Thus, of the seven PZA-resistant Mtb isolates tested,
five were inhibited by Exo-MS alone. Exo-MS + PZA
combination did not change the MIC.
Table 8 shows the GU values of DFO-B and DFO-B +
PZA combination on seven PZA-resistant isolates. For
the two non-MDR PZA-resistant isolates, MIC of DFO-
B alone was 0.5 mg/mL and it decreased to 0.25 mg/mL
for DFO-B + PZA combination. For three of the five
MDR PZA-resistant isolates, MIC of DFO-B alone was
1.0 mg/mL. For two of these three isolates, MIC of
DFO-B + PZA combination decreased to 0.25 mg/mL.
Thus, of the seven isolates of PZA-resistant Mtb, five
were susceptible to DFO-B and DFO-B + PZA.
Table 3 Protocol for MGIT-DST of MDR-Mtb with DFO-B alone and in combination with INH and RIF





MGIT tube except GC
No. of Middle Brook tubes
GC MDR
1 INH 8.3 μg/mL 100 μL 0.1 μg/mL 1 1
2 RIF 83 μg/mL 100 μL 1.0 μg/mL 1
3 DFO-B + INH 160 mg/mL + 8.3 μg/mL 12.5 μL + 100 μL 0.25 mg/mL and 0.1 μg/mL 1
4 DFO-B + INH 160 mg/mL + 8.3 μg/mL 25 μL and 100 μL 0.5 mg/mL and 0.1 μg/mL 1
5 DFO-B + INH 160 mg/mL + 8.3 μg/mL 50 μL and 100 μL 1.0 mg/mL and 0.1 μg/mL 1 1
6 DFO-B + RIF 160 mg/mL + 83 μg/mL 12.5 μL + 100 μL 0.25 mg/mL and 1.0 μg/mL 1
7 DFO-B + RIF 160 mg/mL + 83 μg/mL 25 μL + 100 μL 0.5 mg/mL and 1.0 μg/mL 1
8 DFO-B + RIF 160 mg/mL + 83 μg/mL 50 μL + 100 μL 1.0 mg/mL and 1.0 μg/mL 1
9 DFO-B 160 mg/mL 12.5 μL 0.25 mg/mL 1 1
10 DFO-B 160 mg/mL 25 μL 0.5 mg/mL 1
11 DFO-B 160 mg/mL 50 μL 1.0 mg/mL 1
12 DFO-B + FeCl3 160 mg/mL + 80 mg/mL 50 μL + 50 μL 1.0 mg/mL and 0.5 mg/mL 1
Table 4 Protocol for MGIT-DST for PZAR-Mtb with DFO-B alone and in combination with PZA
No Drug Initial Concentration of
the drug preparation
Volume added
to MGIT for Test
Final Concentration in MGIT
tube except GC
No. of PZA tubes
GC PZAR
1 PZA 8 mg/mL 100 μL 0.1 mg/mL 1 1
2 DFO-B + PZA 160 mg/mL + 8 mg/mL 12.5 μL + 100 μL 0.25 mg/mL and 0.1 mg/mL 1
3 DFO-B + PZA 160 mg/mL + 8 mg/mL 25 μL + 100 μL 0.5 mg/mL and 0.1 mg/mL 1
4 DFO-B + PZA 160 mg/mL + 8 mg/mL 50 μL + 100 μL 1.0 mg/mL and 0.1 mg/mL 1
5 DFO-B 160 mg/mL 12.5 μL 0.25 mg/mL 1 1
6 DFO-B 160 mg/mL 25 μL 0.5 mg/mL 1
7 DFO-B 160 mg/mL 50 μL 1.0 mg/mL 1
8 DFO-B + FeCl3 160 mg/mL + 80 mg/mL 50 μL + 50 μL 1.0 mg/mL and 0.5 mg/mL 1
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The control tubes with ferric citrate added showed GU
value of 400 for all the isolates.
Bacteriostatic or bactericidal effect of the siderophores in
vitro
When the inhibited isolates showing GU value of <100
were re-inoculated into fresh siderophore-free and drug-
free Middlebrook 7H9 medium, the distinction between
bacteriostatic and bactericidal effect of the siderophores
(and their combinations) could be inferred based on the
GU values. If the GU value of re-inoculated tube was
<100, the original siderophore-drug combination was
considered bactericidal. If the GU value of re-inoculated
tube was 400, the original siderophore-drug combination
was considered bacteriostatic.
After 14 days of re-inoculation into fresh medium, the
GU values were <100 for two isolates inhibited by Exo-MS
+ INH, three of the nine isolates inhibited by DFO-B +RIF
and three of the five isolates inhibited by DFO-B + PZA.
However, at the end of 35 days, all concentrations of side-
rophores and their combinations with drugs were found to
be bacteriostatic for all isolates, with GU values of 400.
Discussion
Tubercle bacilli acquire iron from a mammalian host for
their growth. Excess iron in vivo promotes Mtb infection
and may impair macrophage function affecting innate
immunity. A study using female Balb/C mouse infected
with Mtb showed that iron overloading significantly re-
duced the bactericidal activity of INH and completely
neutralized the bacteriostatic activity of ethambutol [11].





Exo-MS (mg/mL) Exo-MS (mg/mL) + INH 0.1 μg/mL Exo-MS (mg/mL) + RIF 1.0 μg/mL Ferric citrate +
Exo-MS (mg/mL)
0.125 0.25 0.5 0.125 0.25 0.5 0.125 0.25 0.5 0.5
1 400 400 400 400 400 400 400 400 400 400
2 400 400 0 400 400 0 400 400 0 400
3 400 400 0 400 400 0 400 400 12 400
4 400 400 400 400 400 400 400 400 400 400
5 400 400 253 400 400 105 400 400 131 400
INFERENCE R R S n = 2 R R S n = 2 R R S n = 2 R
GU value of GC for all five isolates was 400. GU value in INH- and RIF-containing medium for all isolates was also 400. R resistant, S Susceptible. If the GU value of
the drug-containing tube is ≥100, the interpretation is Resistant by the MGIT instrument. If the GU value of the drug tube is <100, the interpretation is Susceptible
(n = no. of isolates susceptible)
Inhibitory effect of Exo-MS, Exo-MS + INH, Exo-MS + RIF on five clinical isolates of MDR-Mtb (INH-, RIF- and PZA-resistant). The medium used was Middlebrook 7H9
broth, pH = 7 incubated at 37 °C for14 days in the MGIT instrument





DFO-B (mg/mL) DFO-B (mg/mL) + INH 0.1 μg/mL DFO-B (mg/mL) + RIF 1.0 μg/mL Ferric citrate +
DFO-B (mg/mL)
0.25 0.5 1.0 0.25 0.5 1.0 0.25 0.5 1.0 1.0
1 400 400 0 400 400 0 400 400 0 400
2 400 400 0 400 400 0 400 400 0 400
3 400 0 0 400 0 0 400 0 0 400
4 400 0 0 400 0 0 400 0 0 400
5 400 400 400 400 400 400 400 400 400 400
6 400 400 0 400 0 0 400 0 0 400
7 400 400 0 400 400 0 400 400 0 400
8 400 0 0 400 0 0 400 0 0 400
9 400 0 0 400 0 0 400 0 0 400
10 400 400 0 400 400 0 400 400 0 400
INFERENCE R S n = 4 S n = 9 R S n = 5 S n = 9 R S n = 5 S n = 9 R
GU value of GC for all ten isolates was 400. GU value in INH- and RIF-containing medium for all isolates was also 400. R resistant, S susceptible. If the GU value of
the drug-containing tube is ≥100, the interpretation is Resistant by the MGIT instrument. If the GU value of the drug tube is <100, the interpretation is Susceptible
(n = no. of isolates susceptible)
Inhibitory effect of DFO-B, DFO-B + INH, DFO-B + RIF on ten different clinical isolates of MDR-Mtb (INH-, RIF- and PZA-resistant). The medium used was Middlebrook
7H9 broth, pH = 7 incubated at 37 °C for 14 days in the MGIT instrument
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There are various strategies that the human body has
adapted to safeguard the iron. Iron retention by the reticu-
loendothelial system [12] and mild anemia which is a com-
mon occurrence in TB patients are examples of host
mechanisms to ensure iron-deficient conditions in the body
[13, 14]. Though these natural processes exist, restricting
the spread of MDR-Mtb in the human population is still a
major problem.
MDR-Mtb strains are defined as those that are resistant
to INH and RIF, both of which are important anti-TB drugs.
PZA is also a first-line anti-TB drug. All the three drugs are
bactericidal to susceptible strains of Mtb and hence were
chosen for this study. Ethambutol was not selected since it
is bacteriostatic to susceptibleMtb strains.
For the first time, MIC of siderophores has been deter-
mined using the MGIT-DST method for drug-resistant
Mtb isolates. It is important to note that the anti-TB activ-
ities of Exo-MS and DFO-B by themselves were significant.
Inhibitory effect of Exo-MS on MDR-Mtb isolates was
determined in the Middlebrook 7H9 medium with a
neutral pH. Two of the five MDR-Mtb isolates tested
were susceptible to Exo-MS. The same numbers were
susceptible to its combination with INH and RIF. Due to
limited availability of Exo-MS, only five isolates of MDR-
Mtb could be tested with it.
When the inhibitory effect of DFO-B on MDR-Mtb iso-
lates was determined, nine out of ten isolates of MDR-Mtb
tested were found to be susceptible to DFO-B. The same
numbers were susceptible to its combination with INH
and RIF, though at a lower DFO-B concentration for some.
Inhibitory effect of Exo-MS and DFO-B on PZA-resistant
Mtb isolates was determined in a modified Middlebrook
7H9 medium with pH 5.9. The standard growth medium
used for testing INH and RIF is not used for PZA, since
PZA requires acidic pH for activity in vitro. Five of the
seven PZA-resistant Mtb isolates were susceptible to Exo-
Table 7 MGIT-DST of PZAR-Mtb with Exo-MS alone and in combination with PZA
Mtb Isolate Exo-MS (mg/mL) Exo-MS (mg/mL) + PZA 100 μg/mL Ferric citrate +
Exo-MS (mg/mL)
0.125 0.25 0.5 0.125 0.25 0.5 0.5
PZAR isolate 1 0 0 0 0 0 0 400
PZAR isolate 2 0 0 0 0 0 0 400
MDR + PZAR isolate 3 400 0 0 400 0 0 400
MDR + PZAR isolate 4 400 400 400 400 400 400 400
MDR + PZAR isolate 5 400 25 0 400 0 0 400
MDR + PZAR isolate 6 400 317 0 400 237 0 400
MDR + PZAR isolate 7 400 400 400 400 386 253 400
INFERENCE S n = 2 S n = 4 S n = 5 S n = 2 S n = 4 S n = 5 R
GU value of GC for all seven isolates was 400. GU value in PZA-containing medium for all isolates was also 400. R resistant, S susceptible. If the GU value of the
drug-containing tube is ≥100, the interpretation is Resistant by the MGIT instrument. If the GU value of the drug tube is <100, the interpretation is Susceptible
(n = no. of isolates susceptible)
Inhibitory effect of Exo-MS and Exo-MS + PZA on seven PZAR isolates: The medium used was Middlebrook 7H9 broth, pH = 5.9 incubated at 37 °C for14 days in the
MGIT instrument
Table 8 MGIT-DST of PZAR-Mtb with DFO-B alone and in combination with PZA
Mtb Isolate DFO-B (mg/mL) DFO-B (mg/mL) + PZA 100 μg/mL Ferric citrate +
DFO-B (mg/mL)
0.25 0.5 1.0 0.25 0.5 1.0 1
PZAR isolate 1 209 41 0 0 0 0 400
PZAR isolate 2 129 0 0 0 0 0 400
MDR + PZAR isolate 3 400 400 0 7 0 0 400
MDR + PZAR isolate 4 400 400 179 400 400 400 400
MDR + PZAR isolate 5 400 400 0 0 0 0 400
MDR + PZAR isolate 6 400 400 400 400 400 400 400
MDR + PZAR isolate 7 400 400 0 400 400 0 400
INFERENCE R S n = 2 S n = 5 S n = 4 S n = 4 S n = 5 R
GU value of GC for all seven isolates was 400. GU value in PZA-containing medium for all isolates was also 400. R resistant, S susceptible. If the GU value of the
drug-containing tube is ≥100, the interpretation is Resistant by the MGIT instrument. If the GU value of the drug tube is <100, the interpretation is Susceptible
(n = no. of isolates susceptible)
Inhibitory effect of DFO-B and DFO-B + PZA on seven PZAR isolates: The medium used was Middlebrook 7H9 broth, pH = 5.9 incubated at 37 °C for 14 days in the
MGIT instrument
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MS alone. There was no change in the MIC in combination
with PZA. Similarly, five of these isolates were susceptible
to DFO-B alone and also to DFO-B + PZA. For four of
these isolates, the MIC of DFO-B decreased to half when
used in combination with PZA.
A significant observation was that the inhibitory activ-
ity of the siderophores was abolished when excess iron
was added in the medium. This proves that the anti-TB
effect of the siderophores is solely due to their ability to
deprive pathogens of iron. This makes it imperative to
use the desferri form of siderophores in such studies.
For all isolates, the siderophore concentrations used
were found to be bacteriostatic. This could be beneficial
in restricting multiplication of the pathogen in vivo, thus
participating in controlling the infection.
The tubercle bacilli down-regulate iron-containing
proteins during iron-deficiency [15]. Therefore, iron-
deprivation by Exo-MS and DFO-B may result in inhib-
ition or inactivation of proteins and enzymes involved in
vital functions required for drug resistance such as cell
wall integrity. Perhaps Exo-MS and DFO-B may act as
facilitators for antibiotics across the cell membrane due
to increased cell permeability. Therefore, in the presence
of exogenous iron chelators, drug-resistant Mtb could
once again become susceptible to the same drugs.
Middlebrook 7H9 medium contains high levels of iron
which may not represent true physiological concentra-
tions of ferric ions. It could be one of the reasons why
the MIC of the siderophores was high in vitro. Such sus-
ceptibility testing predicts the possible antimicrobial
agent for the treatment of an infection. The clinical out-
come may not be the same due to factors such as host
physiology or other interventions, which cannot be sim-
ulated in laboratory tests. In vivo studies are required to
validate these most promising in vitro results. While
DFO-B is already approved for use to treat iron overload
in thalassemic patients, safety of Exo-MS for therapeutic
use needs to be determined.
We have shown in another study that Exo-MS and
DFO-B do not have any cytotoxic effects in vitro on nor-
mal mammalian cell lines, such as human embryonic kid-
ney cell line HEK-293 and mouse fibroblast cell line NIH/
3 T3 [8]. From the results of the anti-TB activity as well as
the effect on normal mammalian cells, it can be concluded
that Exo-MS at 0.5 mg/mL and DFO-B at 1.0 mg/mL se-
lectively inhibit Mtb without significantly harming normal
mammalian cells.
Conclusions
Our study is the first ever investigation done to evaluate
siderophores as potential agents against drug-resistant
Mtb by MGIT-DST method. Since the work was explora-
tory in nature, few drug-resistant isolates of Mtb were
used. Nonetheless, it has provided a “proof of concept”
that exogenous siderophores such as Exo-MS and DFO-B
could be valuable additions to fight drug-resistant M. tu-
berculosis. In view of the encouraging preliminary results,
new in vitro study with large number of M. tuberculosis
isolates can be carried out.
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